Ratings Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.24 ^USD	-0.44%		+3.70%	+27.99%

May. 15	Transcript : Plus Therapeutics, Inc., Q1 2024 Earnings Call, May 15, 2024
May. 09	Transcript : Plus Therapeutics, Inc. - Special Call

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PLUS THERAPEUTICS, INC.	+27.99%	9.58M	-
IQVIA HOLDINGS INC.	-0.09%	42.12B	B
LONZA GROUP AG	+49.62%	42.05B	A
CELLTRION, INC.	-4.96%	29.18B	C
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B	B
BIO-TECHNE CORPORATION	+8.61%	13.21B	B+
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B	B+
MEDPACE HOLDINGS, INC.	+28.31%	12.16B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes